



University of Essex

Department of Economics

Discussion Paper Series

No. 707 January 2012

Strategic Immunization and Group Structure

Andrea Galeotti and Brian W. Rogers

Note : The Discussion Papers in this series are prepared by members of the Department of Economics, University of Essex, for private circulation to interested readers. They often represent preliminary reports on work in progress and should therefore be neither quoted nor referred to in published work without the written consent of the author.

Strategic Immunization and Group Structure¹

Andrea Galeotti and Brian W. Rogers²

February 1, 2012

Abstract: We consider the spread of a harmful state through a population that is divided into two groups. The groups interact with each other to an extent that is parameterized, capturing the full spectrum from perfectly positive to perfectly negative assortativity. We first consider a central planner who can immunize a fraction of the population to eradicate the harmful state. The optimal policy either divides equally the resources across groups, or concentrates entirely on one group, depending on whether there is positive or negative assortative matching, respectively. Furthermore, the value of the social planner learning the exact level of assortativity is zero when interactions are positively assortative, and is increasing in the intensity of negative assortativity. We then study a game in which agents can, at a cost, achieve immunity. Inter-group interactions generate large asymmetries across groups in many outcomes of interest, such as welfare and prevalence, even when groups are, ex-ante, very similar. Hence, a failing to account for the impact of inter-group interactions may lead to over-estimating underlying differences across groups, and to suboptimal immunization plans.

¹Andrea Galeotti thanks ERC for financial support via ERC-starting grant.

²Galeotti, University of Essex, Department of Economics, agaleo@essex.ac.uk; Rogers, Northwestern University, Kellogg School of Management, MEDS, and Northwestern Institute on Complex Systems, b-rogers@northwestern.edu.

1 Introduction

We study the diffusion of a harmful state through a population. Immunity is available, but is costly. The state is meant to capture various choices or risky behaviors such as tobacco use, in which case immunity is interpreted as a costly commitment to avoid the temptation of smoking. The state could also capture the presence of an electronic virus on a computer network; in this example immunity represents the purchase of anti-virus software, or other costly measures taken to avoid the virus. Another interpretation is that the state represents human infection of various communicable diseases that spread through social contacts; in this case immunity captures a decision to vaccinate oneself.

We model the diffusion process using a standard Susceptible-Infected-Susceptible (SIS) framework, developed originally for epidemiological applications, as in the last interpretation. See [3] and [2] for classical treatments. More recently, the SIS model and its variants have been proposed as useful in understanding a wide variety of processes including such diverse applications as behaviors, information, learning, computer viruses, myopic best response, and imitation dynamics.¹

Briefly, the diffusion process works as follows. Individuals exist in one of two states, S and I , and transition between these states over time. Transitions from I to S occur at a given recovery rate, but transitions from S to I occur at an endogenous rate that depends, in particular, on the expected number of individuals in state I that will be met in a given period. We take a long-run perspective, and base our utility and welfare calculations on the (unique non-degenerate) steady-state of this process, which determines, most importantly, an expected proportion of time that a given individual will be infected with the harmful state.

There are two new features of our framework that enrich the canonical SIS model. *First*, we model the population structure and contact patterns in a detailed manner so that we

¹See, for example, [15], [18] and [16], as well as references therein.

can depart from the restrictive assumption that interactions occur through uniform random matching in a homogenous population. We assume that society is composed of two groups, which we label A and B , and we parameterize the degree of positive or negative assortative interactions between the groups.² At one extreme, individuals have contacts only within their respective groups, and so the diffusion of the harmful state within a group is independent of the diffusion in the other group. At the other extreme, all contacts involve A - B pairs, resulting in a bipartite interaction structure. In this case, the diffusion of the harmful state within one group depends entirely on the diffusion in the other group. The range of cases in between capture varying extents of assortativity. The intermediate case, in particular, involves interaction patterns that are blind to group labels.

Most applications of interest involve some degree of positive assortative matching. As examples, positive assortative interaction has been shown to pervade social networks on many dimensions, including economic status, race, political preferences.³ Many other networks exhibit positive assortative matching for various reasons, including, e.g., computer networks composed of Windows and Mac operating systems. Notwithstanding the prevalence of positively assortative networks, there are important cases in which negative assortative interactions are prevalent. This includes the application to sexual contact networks, in which the predominance of interactions are male-female. More generally, negative assortative interactions are typical of settings in which agents match for reasons relating to complementarities of skill or knowledge.

The *second* aspect is that, while diffusion processes are often studied in a purely stochastic framework, we explicitly model the incentives of agents who are exposed to the diffusion

²[14] consider a setting with positive assortative interactions but there are no incentives in their model. [22] studies numerically a model with vaccination in a two-country setting. Our paper is related more closely to the work of [24] which also considers strategic vaccination in a two-group setting. The focus in [24] is on the stability of equilibria, whereas our analysis explores different economic questions about eradication policies and comparative statics.

³There is a large literature on homophily in social networks. Important early work is contained in [19] and [20]. Examples of more recent work include [21], [23], and [9].

process. In the last two decades some progress has been made towards incorporating certain aspects of incentives into epidemiological diffusion models.⁴ This research has identified important effects of modeling agents' incentives, demonstrating crucial differences with the earlier models that are purely stochastic in nature. Our paper contributes to this line of work by modeling the immunization decision of individuals in a strategic setting. In particular, we assume that all agents simultaneously decide whether or not to undertake a costly immunization.⁵ The cost of the immunity must be weighed against the expected cost of exposure to the harmful state during the diffusion process. As such, individuals anticipate the consequences that their collective immunization decisions will have on the outcome of the diffusion process, and decide optimally under these beliefs.

A game theoretic analysis of immunization in a context in which assortativity affects contact patterns is novel and, as we shall see, provides interesting insights on behavior and welfare. In fact, our main results come specifically from the combination of these two factors. We now summarize these findings.

Our first set of results explores the problem of a central planner attempting to eradicate the harmful state (Section 3).⁶ The planner might be a governmental agency deciding how many vaccines to produce for a communicable disease and how to allocate them across the population. Alternatively, the social planner could be a governmental agency that aims to eliminate smoking in schools via an educational program and it has to decide how large the program should be and which students it should target or require to participate. How should the planner's policy depend on the structure of interactions? What information does the government need in order to determine the optimal amount of immunization and how to

⁴The literature in economics dates at least to [8]. Important contributions include [17], [11], [12], [6], [7], [26] and [27].

⁵In a complementary paper, [13] studies the dual roles of vaccination and level of interaction in a game theoretic framework.

⁶[10] also study optimal policies in the presence of social effects. While [10] model social effects in a reduced form, here we explicitly define the process of diffusion. Another difference is that we focus on the effect that assortativity has in the design of optimal policies, an aspect that is not considered by [10].

efficiently distribute the resources to the population?

We show that there is a sharp discontinuity in the optimal eradication policy when we move from positive assortative interactions to negative assortative interactions (Proposition 2). In the former case, the optimal allocation involves splitting the resources equally between the two groups and the minimum budget needed to eradicate the harmful state is independent of the exact degree of positive assortativity. In contrast, when there are negative assortative interactions, the optimal allocation is to first focus resources exclusively on one group until it is fully immunized and then immunize part of the other group. Furthermore, under negative assortative interactions, this minimum necessary budget is decreasing in the degree of negative assortativity, reaching its lowest level when the network of interactions is bipartite. Intuitively, an increase in inter-group interaction increases the externality that one group's immunity exerts on the other and, by concentrating immunity to one group, the social planner can leverage these group-level externalities to reduce the spread of the harmful state.

An important implication of our first result is that in contexts where the harmful state diffuses through social networks that exhibit positive assortativity, it is not a valuable use of resources for a central planner to learn the exact degree of assortativity, as the optimal plan is not sensitive to these details. In contrast, if the harmful state diffuses through social networks that exhibit negative assortativity such as, for example, sexual contact networks, there is value to the social planner in learning the degree of assortativity, as the budget required for eradication depends on that information. In particular, the planner can save on immunity resources the greater is the degree of assortativity, saving the most when the social network is bipartite.

Our second set of results explore equilibrium behavior (Section 4). We posit that an agent can become immune to the harmful state at a cost, which has to be paid at the beginning of the game. The strategic nature of individual immunization decisions in a context in which assortativity affects contact patterns gives rise to the possibility of asymmetric outcomes in

which one group immunizes at a higher level than the other, even when the groups are ex-ante symmetric. As the game is one of strategic substitutes between the groups, such an equilibrium is plausible, but it is not clear under which circumstances, if any, it will occur, and what the associated implications are for prevalence and welfare in the two groups.

We show that when there are positive assortative interactions, ex-ante identical groups necessarily obtain symmetric equilibrium outcomes: the immunization rate is the same across groups, with the consequence that the prevalence of the harmful state and welfare are the same across groups as well. Moreover, all of these outcomes are invariant to the specific level of positive assortativity. In contrast, when there are negative assortative interactions, the equilibrium is highly asymmetric. It is either the case that one group does not immunize at all, or that the other group immunizes completely, or possibly both (Proposition 4). The prevalence of the harmful state is higher in the group with the low immunization rate than in the group with the high immunization rate, yet the group with the low immunization rate has the highest welfare (Proposition 5). Hence, higher infection prevalence is not indicative of lower welfare. Furthermore, the difference between the welfare of the two groups is higher when the degree of negative assortativity is higher, thereby reaching a maximum in a bipartite social network. We also show that the prevalence of each group may be non-monotonic with the degree of assortativity (Proposition 6).

Finally, we consider the possibility that there is an underlying economic asymmetry between the groups (Section 5). We capture this asymmetry by imposing different immunization costs in the two groups.⁷ This would be the case if, for example, one group is wealthier than the other, so that its cost of immunization is lower relative to the marginal benefit of being in state S over state I . In this context we show that the introduction of small initial differences across groups is amplified by a social multiplier, and this social multiplier is increasing in

⁷Alternative forms of asymmetries, such as different infection rates across groups, are discussed in Section 5.

cross-group interaction, even when there are positive assortative interactions (Proposition 7 and Corollary 1).

Broadly, our analysis shows how the details of group interactions have a profound effect both on how a planner should respond to reducing the prevalence of the state and on the equilibrium outcomes of the diffusion process. Group interactions tend to generate large asymmetries across groups in the outcomes of interest, namely welfare and prevalence, even when groups are, ex-ante, very similar. It is therefore important to account for the structure of interactions when studying, empirically, the sources of observed asymmetries in behavior and diffusion outcomes across groups. Failing to account for the impact of inter-group interactions may lead to overestimating the underlying differences across groups. Moreover, when interactions are negatively assortative, we demonstrate that the planner will generally have to resolve a tension between the optimal reduction of prevalence and reducing asymmetries in welfare across the groups, whenever fairness is a consideration.

2 A model of social diffusion

There is a continuum population. Individuals are classified into two groups each of mass one, labeled A and B . The groups serve purely as labels; from a modelling perspective, individuals in the two groups are identical in every respect. At each point in time, every individual interacts with k other individuals. A proportion $\beta \in [0, 1]$ of the interactions are with individuals in the same group while the remaining interactions are with individuals in the other group. Thus β measures the extent of positive or negative assortativity of interactions. At one extreme $\beta = 1$, there are no interactions across the groups, and society is segregated into two separate networks. When $\beta > 1/2$, there is positive assortative interaction, in the sense that the majority of contacts involve intra-group interactions. At $\beta = 1/2$, the interaction structure is independent of group labels. For $\beta < 1/2$, most interactions involve

individuals from opposite groups and we say that there is negative assortative interaction; at $\beta = 0$, the network becomes bipartite, so that all interactions are across groups.

We model the diffusion of a harmful state through this population in continuous time. For the moment, assume that a proportion π_g of group $g \in \{A, B\}$ has immunity.⁸ At each point in time, each individual who is not immunized exists in one of two states, which we call Susceptible (S) and Infected (I). The states of non-immunized individuals change over time. The transitions between states S and I depend on (i) the patterns of interactions between individuals, (ii) the proportion of individuals with immunity, (iii) the rate of infection, and (iv) the recovery rate.

Formally, let ρ_g be the proportion of the non-immunized group g individuals who are in state I . Define θ_g as the probability that a randomly chosen contact of a group g individual is infected. By definition, we have

$$\begin{aligned}\theta_A &= \beta(1 - \pi_A)\rho_A + (1 - \beta)(1 - \pi_B)\rho_B \\ \theta_B &= \beta(1 - \pi_B)\rho_B + (1 - \beta)(1 - \pi_A)\rho_A.\end{aligned}\tag{1}$$

A group g individual in state S becomes infected at a rate $\nu\theta_g k$, where ν is the per-contact rate of infection. When ν is small, which is typically the relevant case, this quantity approximates the chance of becoming infected through independent interactions with each of the k neighbors. Individuals in state I transition to state S at a rate δ . Define $\tilde{\lambda} = \nu/\delta$ as the ratio of the rate of infection to the rate of recovery. Steady-state outcomes are characterized by a stable prevalence in the two groups, where the transition rates between S and I are balanced. We have

$$\frac{\partial \rho_g}{\partial t} = (1 - \rho_g)\nu\theta_g k - \rho_g\delta = 0,$$

⁸We assume throughout the paper that immunity is perfect: an agent with immunity cannot be infected by the harmful state. The analysis is easily extended, without additional insights, to the case where immunity is imperfect.

for $g = A, B$. The first term is the in-flow from individuals in state S : the fraction of non-immunized players who are not infected, $1 - \rho_g$, times the rate of infection, $\nu\theta_g k$. The second term is the out-flow: each non-immunized infected agent recovers at a rate δ . Now define $\lambda = k\tilde{\lambda}$ as the intensity of infection. As will be clear below, the effect of k , ν and δ is summarized by the single parameter λ in the analysis. Solving the condition above we obtain:

$$\rho_g = \frac{\lambda\theta_g}{\lambda\theta_g + 1}. \quad (2)$$

We define the prevalence of group g as the proportion of agents in group g that have adopted the harmful state, i.e., $P_g = (1 - \pi_g)\rho_g$, with total prevalence given by $P = P_A + P_B$.

Using standard arguments, one can show the following:

Observation 1 For any given intensity of infection $\lambda > 0$, degree of assortative interaction $\beta < 1$ and a pair of immunization levels (π_A, π_B) , there exists either (i) a unique steady-state in which no agent is infected, i.e., $\rho_g = 0$, $g \in \{A, B\}$, or (ii) two steady-states, one in which no agent is infected and the other with a positive, though potentially different, level of infection in both groups. In case (ii) the unique steady-state with positive level of infection is globally stable.⁹

Since the groups are inherently identical, when dealing with asymmetric outcomes, we focus, without loss of generality, on the case $\pi_A < \pi_B$.

The extent to which individuals in the two groups interact puts a particular structure on the way that their steady state outcomes relate to one another. These relationships depend crucially on whether matchings are positively or negatively assortative, as we now demonstrate.

Proposition 1 *In the steady state with positive level of infection the following holds:*

1. Suppose $\beta < 1/2$. $\pi_A < \pi_B$ iff $\rho_A < \rho_B$ iff $\theta_A < \theta_B$ iff $P_A > P_B$

⁹This result can be shown through a straightforward modification of standard results in the SIS framework as can be found, for example in [28].

2. Suppose $\beta > 1/2$. $\pi_A < \pi_B$ iff $\rho_A > \rho_B$ iff $\theta_A > \theta_B$ iff $P_A > P_B$

We note that regardless of the degree of assortativity, the group with the lower immunization rate experiences higher prevalence. When interactions are negatively assortative, this same group experiences a *lower* level of infection among the non-immunized agents and a lower proportion of infected neighbors. On the other hand, when interactions are positively assortative, the group with the lower immunization rate experiences a higher level of infection among the non-immunized and a higher proportion of infected neighbors.

In what follows, we first study the problem of a planner who allocates a budget of immunizations with the aim of eradicating the harmful state from the population. We then turn to the equilibrium analysis. There, agents choose whether to become immune at a cost, or to be exposed to the diffusion process. In both cases, we assume that agents are concerned with the steady state outcome, and that the outcome of the diffusion process is the unique positive-valued steady state prevalence, when it exists. Notice that Proposition 1 applies to any pair of immunization rates (π_A, π_B) . We will make use of it in the analysis when considering optimal immunization plans as well as equilibrium outcomes.

3 Eradication of Infection

We begin our analysis by considering the problem of a central planner whose objective is to eradicate the harmful state. We ask two questions. First, what is the smallest amount of immunization the social planner requires to eradicate the harmful state? Second, how should the social planner allocate that immunity across the population so as to achieve eradication? We solve for the optimal immunization plan subject to the parameters that describe the transmission rate of the undesirable state, λ , as well as the structure of interactions, as

captured by β .¹⁰

The planner might be a government deciding how many vaccines for a communicable disease to produce and how to allocate them across distinct groups. Alternatively, we may think that a governmental agency has some resources to use towards reduce smoking in schools via an educational program and it has to decide how large the educational program should be and which students should attend the program. Under reasonable conditions on the cost of production of immunizations (e.g., constant marginal cost), the objective to eradicate the undesirable state is equivalent to the objective to maximise social welfare net of immunization costs.¹¹ Interestingly, the conclusion that a social planner would find full eradication to be optimal, if indeed costs are small enough that it prefers some action to taking no action, appears in other analyses, including [25] and [5].

What information does the government need to efficiently decide the optimal policy to eradicate the infection? Should immunizations be allocated symmetrically or concentrated on one group? How should the planner's actions depend on the structure of interactions? We find that the answer to these questions depends crucially on whether the interaction patterns are positively or negatively assortative.

Proposition 2 *For every (λ, β) there exists a threshold $\bar{\pi}^*$ such that eradication is possible if and only if the mass of immunizations available to the social planner is $\bar{\pi} \geq \bar{\pi}^*$.*

When there are positive assortative interactions, the threshold $\bar{\pi}^$ is independent of β and eradication is obtained by dividing $\bar{\pi}^*$ equally across groups, i.e. $\pi_A = \pi_B = \bar{\pi}^*/2$.*


¹⁰There is a literature on the difficulties of inducing discretionary immunization due to the effect of strategic substitutes. See, for example, [12], [4], [6]. As our goal is specifically to study the impact of interaction patterns across populations, we focus on the case in which the planner can directly implement the desired outcome.

¹¹If the cost of production of immunization is sufficiently convex, the amount of immunization that maximizes social welfare would not result in eradication. In this case, we would be interested in identifying the allocation that the social planner will implement to minimize total prevalence, given a certain available mass of immunization. The answer is similar to the one proposed in proposition 2: when there are positive assortative interactions, total prevalence is minimized by dividing the immunizations equally across groups; when there are negative assortative interactions, total prevalence is minimized when immunizations are concentrated as much as possible on one group.

When there are negative assortative interactions, the threshold $\bar{\pi}^*$ is strictly increasing in β and eradication is obtained by concentrating $\bar{\pi}^*$ as much as possible on one group, i.e., $\pi_B = \min\{1, \bar{\pi}^*\}$ and $\pi_A = \max\{0, \bar{\pi}^* - \pi_B\}$.

The proof of Proposition 2 develops in two steps. In the first step, we fix the division of immunity across groups and determine, for this division, the smallest mass of immunization needed to eradicate the disease. In the second step, we determine the allocation that minimizes this threshold level of immunization needed to eradicate the disease.

Proposition 2 shows that there is a sharp discontinuity in the optimal eradication policy of the planner when we move from positive assortative interactions to negative assortative interactions. Figure 1(a) illustrates how the minimum level of immunization that the social planner needs to eradicate the undesirable state, denoted by $\bar{\pi}^*$, changes with the degree of assortative interaction. Figure 1(b) illustrates how the optimal allocation of $\bar{\pi}^*$ changes with the degree of assortative interaction.



(a) Minimum level of immunization needed for eradication.

(b) Optimal allocation of immunization.

Figure 1: Optimal eradication policy, $\lambda = 1.5$, $\beta \in [0, 1]$.

When there are positive assortative interactions, the threshold $\bar{\pi}^*$ is higher than in the case of negative assortative interactions and the planner eradicates the undesirable state by

splitting equally the resources for immunization among the two groups. The minimum level of immunizations that the social planner needs for eradication is given by $\bar{\pi}^* = 2(1 - 1/\lambda)$ and it has a very natural interpretation: it is equal to the value that total prevalence would take in the absence of any immunity in the population. In this sense, one can think of achieving eradication under positive assortative interaction as being equivalent to providing immunity to every infected individual at a given moment in the steady-state of the diffusion process.

When there are negative assortative interactions the minimum level of immunization needed to eradicate the harmful state is decreasing in the intensity of negative assortativity, reaching therefore the minimum level when the network of interactions becomes bipartite.¹² Moreover, eradication is obtained by allocating immunity exclusively to one group, and then allocating immunity to the other group, if necessary, only once the first group is fully immunized. Even though the intensity of infection has not changed, an increase in the intensity of interactions across groups increases the externalities that one group exerts on the other and, by concentrating immunity to one group, the social planner can leverage these group-level externalities to further reduce the spread of the harmful state.

Proposition 2 illustrates when and why it is important to incorporate the details of the interaction structure into the design of eradication policies. Consider, for example, a social planner who implements an eradication policy ignoring groups label and assumes interactions result from uniform random matching, as in the classical treatments of SIS. In this case, to eradicate the infection, the social planner will allocate randomly to the population a mass of immunizations $\bar{\pi}^* = 2(1 - 1/\lambda)$. In view of Proposition 2, this implies that in contexts where the harmful state diffuses through a positively assortative network, there is no value for the social planner to learn the exact details of the interaction structure, i.e., the value of β . In contrast, if the harmful state diffuses through social networks that exhibit negative

¹²The influential work of [1] provides a result that eradication can be easier to achieve in the presence of population heterogeneity. A related result is obtained in [13] under particular assumptions.

assortativity, as in sexual contact networks, there is a positive value for the social planner to learn the exact value of β , since this information allows the social planner to achieve the goal of eradication while using a smaller budget of (presumably costly) immunization. This benefit is greatest when the social network is bipartite. In fact, as β decreases from $1/2$ the benchmark policy of allocating randomly $\bar{\pi}^* = 2(1 - 1/\lambda)$ across groups produces an over-investment of resources which gets increasingly worse relative to the optimal eradication policy.

4 Immunity in a decentralized game

We turn now to assessing the outcomes that might be expected in the absence of any action taken by a planner. Before the diffusion process starts, individuals may choose, at a cost, to immunize themselves. We model this decision as a simultaneous choice game in which agents anticipate the effects of aggregate immunization on the diffusion outcomes. Formally, the action of agent i is $a_i \in \{0, 1\}$, where $a_i = 0$ is interpreted as no immunization. Immunization, when taken, is perfect.

Individuals receive a flow utility of one in state S and zero in state I . Individuals are infinitely patient, so that utility is measured by the limiting proportion of time in state S . Denote the cost of immunization by $c > 0$. An agent who immunizes receives utility $1 - c$, since she is never infected but must pay for the immunity. On the other hand, a group g agent who does not immunize saves the cost, but spends a proportion ρ_g of time in state I , obtaining utility $1 - \rho_g$. Importantly, the steady state values of ρ_g depend on the immunization decisions of individuals in both groups. Thus, immunization decisions are optimal if (and only if) $\pi_g > 0$ implies $\rho_g \geq c$ and $\pi_g < 1$ implies $\rho_g \leq c$. In particular, at an interior equilibrium it must be that

$$\rho_A = \rho_B = c. \tag{3}$$

Having introduced immunization cost, we will be concerned with welfare in the two groups.

There are two costs in the model: the explicit cost of immunization and the opportunity cost of being infected. We define the welfare of group g as the expected utility of a randomly selected agent, i.e.,

$$W_g = 1 - \pi_g c - (1 - \pi_g) \rho_g.$$

Our interest is in understanding how the pattern of interactions affects the equilibrium immunization rates of both groups, and consequently their prevalence and welfare.

4.1 Equilibrium characterization

We first observe that if the intensity of infection λ is sufficiently low, or the cost of immunization c is sufficiently high, then in equilibrium no player will immunize. We have:

Proposition 3 *If $\lambda(1 - c) < 1$ there is a unique equilibrium and it is such that no player immunizes.*

The idea behind Proposition 3 is easy to understand. The smaller is the intensity of infection, λ , the lower will be the steady-state prevalence, all else equal, and so the lower will be the incentive to immunize. On the other hand, given any level of prevalence, the incentive to immunize is decreasing in its cost. It is never optimal to immunize when $c > 1$, since an individual can never gain more than the difference in utility between being susceptible and infected from immunity. Notice, though, that the threshold, below which no individual immunizes, is independent of β . In light of these observations, we can now restrict attention to the case in which immunization decisions are non-trivial.

Assumption 1 $\lambda(1 - c) > 1$.

We maintain Assumption 1 throughout the rest of the analysis. We can now summarize our characterization of equilibria.

Proposition 4 *For every (λ, β, c) there is exactly one stable equilibrium. When there is positive assortative interaction the stable equilibrium is symmetric, interior, and constant in β . When there is negative assortative interaction the stable equilibrium is asymmetric and such that either $\pi_A = 0$ or $\pi_B = 1$ (possibly both).*

The Appendix contains a complete characterization of equilibria and their stability properties.^{13,14} We offer here a rough intuition that underlies this result. First, recall from the equilibrium condition (3) that, at an interior equilibrium, it must be that the proportion of non-immunized agents that are infected in the two groups is the same, i.e., $\rho_A = \rho_B$. The steady-state condition (2) then implies that for an agent in either group, the expected proportion of neighbors that is infected is the same, i.e., $\theta_A = \theta_B$. For these two conditions to hold, it is necessary that immunization rates are symmetric across groups, i.e., $\pi_A = \pi_B$. Hence, any interior equilibrium is necessarily symmetric.¹⁵ Once that is known, it is easy to explicitly solve for the equilibrium immunization rate, which gives $\pi = 1 - 1/(\lambda(1 - c))$. Notice that this rate is indeed interior under Assumption 1.

By this argument any additional equilibrium must be asymmetric and involve a boundary solution. When there is positive assortative interaction, it is impossible to satisfy the equilibrium conditions at two distinct values of $\pi_A < \pi_B$. In contrast, when there is negative assortative interaction, the fact that most interactions are inter-group implies that one group free-rides off the high immunization rate of the other group. This is rational because the high-immunity group interacts mostly with the low-immunity group, which has higher prevalence, justifying the cost of their immunizations. The low-immunity group, meanwhile, takes

¹³When $\beta < 1/2$, the symmetric interior equilibrium exists but it is unstable. To understand why this is so, note that as β decreases, the degree of strategic substitutability between the groups' immunization rates increases. That is, the best response of each group to the other group's immunization rate is becoming more sensitive. When $\beta = 1/2$, the slope of the reaction functions at the interior equilibrium is unity, and so it is at this point that the interior equilibrium switches from being stable to unstable.

¹⁴In perhaps the most closely related paper, [24] obtains results on the existence and stability of equilibria in a related setting.

¹⁵The knife-edge case $\beta = 1/2$ is the only exception, in which case there is a continuum of interior equilibria.

advantage of the fact that most of their interactions are with the high-immunity group which has low prevalence. The consequence is that the free-riding group, while infected at a higher rate, obtains higher welfare because their high prevalence is necessarily more than offset by the savings in immunization costs. That is, higher infection prevalence is not indicative of lower welfare; indeed, the opposite is true. We have:

Proposition 5 *Consider the case of negative assortative interactions. In the stable equilibrium, the group that immunizes less has both higher prevalence and higher welfare.*

When there is positive assortative interaction, both groups immunize at interior rates that are constant in β , whereas in the case of negative assortative interaction one of the groups is either fully immunized or not immunized at all. Hence, equilibrium group immunization rates are discontinuous around $\beta = 1/2$. Nevertheless, the resulting prevalence in each of the two groups, as well as their welfare, are continuous in β . Furthermore, when there are positive assortative interactions, all interesting outcomes like prevalence and welfare are constant in β . However, this neutrality result in the degree of assortativity on equilibrium outcomes no longer holds when there are negative assortative interactions. In fact, in this case the effect of β on group prevalence, immunization rate and welfare is subtle, and cannot always be signed. We turn now to these comparative statics.

We present Figure 2 to illustrate features of the comparative statics. In the figure, the cost of immunization c is constant throughout, whereas the intensity of infection λ takes values that increase from the left column to the right column. The higher is $\lambda(1 - c)$ the higher is the incentive to immunize, all else equal. So, when we move from the left column to the right column we are considering environments in which, ex-ante, it is more profitable to invest in immunization. The three rows depict immunization rates (top), prevalence (middle) and welfare (bottom), where group A is shown in dashed blue, group B in dotted red, and the total population in solid green.




Figure 2: In all cases c is constant (at 0.86). The value of λ increases from the left column to the right column (taking values 9, 12, 16). Each row depicts different quantities with group A in dashed blue, group B in dotted red, and the total in solid green. Row 1: Immunization rates, Row 2: Prevalence, Row 3: Welfare.

As we have already discussed the equilibrium under positive assortative interactions, we focus here on negative assortativity. In this range, consider the extreme cases. When $\beta = 0$, it is always the case that group A completely free rides on group B , and that there remain some non-immunized agents in group B , so that $0 = \pi_A < \pi_B < 1$. This is true because when the network is bipartite, the infection will be eradicated even when there remain some non-immunized individuals in group B , due to herd immunity. Consider now values of β near $1/2$. When the incentive to immunize is sufficiently high, $\lambda(1 - c) > 2$, the total immunization rate in society is greater than 50%, and so the equilibrium involves $\pi_B = 1$, as in the third column. Otherwise, the equilibrium involves $\pi_A = 0$, as in the first two columns.

These observations characterize which boundary conditions bind the equilibrium immunization rates near the extreme cases of $\beta = 0$ and $\beta = 1/2$ for negative assortative interactions. This is useful because, as we will see, the comparative statics of the equilibrium are very different in these cases.

Consider first the case where the incentive to immunize is high, so that $0 < \pi_A < \pi_B = 1$ near $\beta = 1/2$. Start from uniformly random interactions and consider decreasing β from $1/2$. Since group B is fully immunized, the free-riding of group A becomes more effective and this causes the immunization rate of group A to decrease, until nobody in group A immunizes. As this immunization rate drops, the prevalence in group A is increasing, due to the equilibrium condition that ρ_A is constant at value c . But even as the prevalence in group A increases, so does their welfare.

Once we are in a region where group A completely free-rides ($\pi_A = 0$), prevalence in group A now changes directions and begins to decrease with a further decline in β , since the immunization rate in group A is now constant at zero. This fact gives rise to the possibility of a non-monotonicity in prevalence, as illustrated in the middle-right panel of Figure 2. While there is an interval of β in which both boundary conditions bind ($\pi_A = 0$ and $\pi_B = 1$), at some point the prevalence in A becomes low enough that it is no longer optimal for group B to fully immunize. At this point $\pi_B < 1$, which holds until we reach $\beta = 0$.

Notice that, with this pattern of interactions, total immunizations are always lower than when $\beta > 1/2$ (first row, third column), while the total prevalence is non-monotonic (second row, third column). Despite the non-monotonicity in prevalence, it is always true that welfare strictly increases as β decreases, reaching its maximum value at the bipartite network.

Turning now to the remaining case when the stable equilibrium transitions to immunization levels with $0 = \pi_A < \pi_B < 1$, we see that the comparative statics have many possibilities and, consequently, it is not easy to establish monotonicity properties. The first and second columns of Figure 2 fall under these parameters. Indeed, in this case there are two opposing forces

on the immunization decision of group B as β decreases. First, group B interacts more and more with group A which has higher prevalence, putting upward pressure on π_B . Second, as β decreases the prevalence in group A is decreasing, putting downward pressure on π_B . The net result of these two effects is subtle and depends on the particular parameters in question. In particular, total immunizations and prevalence of group B may well be non-monotonic in β , as in the second column of Figure 2.

From the above discussion, we are able to conclude that when group A fully free-rides, their prevalence increases with β , whereas when group A only partially free-rides, the opposite is true. We derive an even simpler conclusion about welfare. For group B , the high-immunization group, it is always constant, because $\pi_B > 0$ implies that welfare is given by $1 - c$. Finally, although it is much less obvious, we can also show that for group A , welfare is always decreasing in β . This is summarized in the following result.

Proposition 6 *Consider the stable equilibrium when there are negative assortative interactions.*

1. *For the group that immunizes more, welfare is constant in β .*
2. *For the group that immunizes less, welfare is decreasing in β .*

Furthermore, for the group that immunizes less, prevalence is either (i) increasing in β if $\lambda(1 - c) < 2$, or (ii) first increasing in β for $\beta < 1/\lambda(1 - c)$, and then decreasing in β thereafter, if $\lambda(1 - c) > 2$.

4.2 Efficiency properties of equilibrium

We are now in a position to relate the equilibrium characterization to the properties of the social planner's problem.

As we have already anticipated in Section 2, we observe that when immunization has marginal cost c , the optimal action for a social planner who wishes to maximize social welfare

is either full eradication or to do nothing. When $\beta > 1/2$, Proposition 2 tells us that to eradicate the harmful state the social planner needs to provide a mass of immunizations which is equal to the steady state value that total prevalence would take in the absence of any immunity in the population. Since the benefit of not being infected by the harmful state is normalized to 1, we have that eradication is better than providing no immunity if and only if $c < 1$. When $\beta < 1/2$, eradication can be achieved for an even smaller cost, and so when $c < 1$ eradication is again optimal.

Notice that the distribution of immunity across groups in equilibrium is efficient. When there is positive assortative interaction, the two groups immunize at the same rate and so total immunity is, in equilibrium, divided equally across groups. When there is negative assortative interaction, the equilibrium allocation of immunity is as asymmetric as possible, conditional on the level of total immunity, since $\pi_A > 0$ only if $\pi_B = 1$.

Given that immunization carries a positive externality, it is of course not surprising that equilibrium immunization rates are inefficiently low. What these observations imply, however, is that the source of inefficiency rests entirely on the aggregate level of immunization. The welfare loss implied by equilibrium immunizations relative to the first-best outcome is highest for intermediate ranges of λ and c . For extreme values of either λ or c , the equilibrium and the first-best immunization rates coincide.

5 Group heterogeneity

So far group labels have been used only to the extent that they influence the interactions among individuals. In reality, there are often underlying differences between individuals of different populations. In this section we investigate equilibrium outcomes when the cost of immunization is group-dependent. Specifically we set the costs at $c_B < c_A$. This specification captures the case where one group has easier access to immunization, or where one group is

richer, so that the cost of immunization is lower relative to the difference in utility between being healthy and infected.¹⁶ As we shall show, the introduction of even small initial differences across groups is amplified by a social multiplier, and the multiplier increases with the intensity of inter-group interactions.

In order to exhibit this point, we focus on positive assortative interactions, i.e., $\beta > 1/2$. Recall that in this case, under symmetric costs, the unique equilibrium involves equal immunization rates and identical outcomes in the two groups. The following proposition characterizes equilibria under asymmetric costs.

Proposition 7 *Suppose $c_B < c_A$ and $\lambda(1 - c_A) > 1$. There exists a $\bar{\beta} > 1/2$ such that: If $\beta \in [1/2, \bar{\beta}]$ in the unique equilibrium all agents in group B immunize, $\pi_B = 1$, while only a proportion of agents in A immunize, $\pi_A \in (0, 1)$; if $\beta \in [\bar{\beta}, 1]$, the unique equilibrium is interior and $\pi_B > \pi_A$.*

An interesting aspect of the characterization is that initial differences between the two groups are amplified by the pattern of interactions via a social multiplier effect.¹⁷ This amplification in fact drives the equilibrium to a boundary solution at $\beta = \bar{\beta}$. In this sense, arbitrarily small differences between the groups result in very asymmetric outcomes as the intensity of positive assortativity decreases. We define by Δ_π the difference between π_B and π_A when $\beta = 1$ and, hence, the diffusion in the two groups is independent. Similarly, Δ_P is the difference between the prevalence of group A and the prevalence of group B when $\beta = 1$. Using our characterization, one obtains that

$$\Delta_\pi = [\pi_B - \pi_A]|_{\beta=1} = \frac{c_A - c_B}{\lambda(1 - c_A)(1 - c_B)} = \Delta_P = [P_A - P_B]|_{\beta=1} > 0$$

¹⁶Other forms of ex-ante asymmetries are possible. For example, one could consider the case where one group has a more effective natural immunity, or a higher rate of recovery, than the other group, i.e., $\lambda_B > \lambda_A$. This case is not identical, but is qualitatively similar, to the cost heterogeneity case. Details are available upon request.

¹⁷Under a complementarity assumption, [13] find a result that emphasizes a different form of heterogeneity.

Corollary 1 *Suppose $c_B < c_A$, $\lambda(1 - c_A) > 1$ and $\beta > 1/2$.*

- *The difference between the equilibrium immunization rate of group B and group A is the product of Δ_π and a social multiplier $\Phi_\pi(\beta, c_A, c_B) > 1$, which is decreasing and convex in β .*
- *The difference between the equilibrium prevalence of group A and group B is the product of Δ_P and a social multiplier $\Phi_P(\beta, c_A, c_B)$, which is decreasing and convex in β .*
- *The difference between the equilibrium welfare of group B and of group A equals $c_A - c_B$ and therefore it is constant in β .*

Overall, Proposition 7 and Corollary 1 illustrate how small initial differences across groups are amplified by a social multiplier, even in the case where there is positive assortative interaction. For all $\beta \geq 1/2$ we have that the immunization rate of the low cost group is higher than the immunization rate of the high cost group and that as β decreases from 1 the immunization rate of the low cost group increases, whereas the immunization rate of the high cost group decreases. Similarly, the prevalence of the low cost group is lower than the prevalence of the high cost group and, as β decreases from 1, the prevalence of the low cost group decreases, whereas the prevalence of the high cost group increases.

In light of these results, we conclude that the structure of group interactions that we study tends to produce highly asymmetric outcomes. The only exception to this tendency is under positive assortative interactions when either the two groups are inherently identical, or they are nearly identical, and the intensity of assortativity is very strong.

6 Conclusion

We have explored the diffusion of a harmful state through a population in an environment where immunization is possible, but costly, and where contact patterns depart from the con-

ventional assumption that interactions occur through uniform random matching. We have first studied the problem of a social planner who designs a policy to eradicate the spread of the harmful state. We have then derived the equilibrium of a game in which agents, averse to the possibility of being infected by the harmful state, choose whether to immunize or not, anticipating the consequence of their choices on the diffusion process.

We have shown that the details of group interactions have a profound effect on how a planner would respond to reducing the prevalence of the harmful state and we have derived when it is more valuable for the social planner to know the exact pattern of interactions. Furthermore, we have proved that inter-group interactions generate large asymmetries across groups in the equilibrium outcomes regarding welfare and prevalence, even when groups are, *ex-ante*, very similar. This suggests that it is important to account for the structure of interactions when studying, empirically, the causes of observed asymmetries in behavior and diffusion outcomes across groups. In particular, failing to account for the effects of group interactions would, in this setting, lead to overestimating the underlying differences across groups.

We conclude with a simple observation that emphasizes the importance of incorporating economic aspects into diffusion models, as has been recognized for some time and is expressed clearly in the work of [6] and [11]. In our equilibrium model total prevalence tends to *decrease* in the intensity of infection λ .¹⁸ The opposite conclusion is obtained in a non-strategic model where immunization decisions do not react to changes in λ . As the intensity of infection increases, equilibrium immunization rates increase to the level that, conditional on not having immunity, the proportion of time infected remains constant ($\rho = c$). Given that the non-immunized individuals are infected at a constant rate, but more individuals are immu-

¹⁸Compare, for example, the equilibrium total prevalence in the middle row of Figure 2 from left to right, as λ increases. For the case $\beta > 1/2$, total prevalence is clearly decreasing in λ . However, fixing a value of $\beta < 1/2$, the effect of λ on equilibrium total prevalence is ambiguous, which is also exemplified in the second row of the figure.

nized, prevalence must decrease. As a result, welfare is constant, as the increased cost of immunization are exactly offset by the decrease in prevalence.

References

- [1] R M Anderson and R M May. Spatial, temporal, and genetic heterogeneity in host populations and the design of immunization programmes. *IMA Journal Of Mathematics Applied In Medicine And Biology*, 1(3):233–266, 1984.
- [2] R.M. Anderson and R.M. May. *Infectious diseases of humans: dynamics and control*, volume 26. Wiley Online Library, 1992.
- [3] N T J Bailey. The mathematical theory of infectious diseases and its applications. 2nd edition. *The mathematical theory of infectious diseases and its applications 2nd edition*, 413, 1975.
- [4] Scott Barrett. Global Disease Eradication. *Journal of the European Economic Association*, 1(2-3):591–600, April 2003.
- [5] Scott Barrett and Michael Hoel. Optimal disease eradication. *Environment and Development Economics*, 12(5):627–652, 2007.
- [6] Chris T Bauch and David J D Earn. Vaccination and the theory of games. *Proceedings of the National Academy of Sciences of the United States of America*, 101(36):13391–4, September 2004.
- [7] B.L. Boulier, T.S. Datta, and R.S. Goldfarb. Vaccination externalities. *The BE Journal of Economic Analysis & Policy*, 7(1):23, 2007.
- [8] D.L. Brito, Eytan Sheshinski, and M.D. Intriligator. Externalities and compulsory vaccinations. *Journal of Public Economics*, 45(1):69–90, 1991.

- [9] F. Echenique, R.G. Fryer, and A. Kaufman. Is school segregation good or bad? *The American economic review*, 96(2):265–269, 2006.
- [10] A. Galeotti and S. Goyal. Influencing the influencers: a theory of strategic diffusion. *The RAND Journal of Economics*, 40(3):509–532, 2009.
- [11] PY Geoffard and Tomas Philipson. Rational epidemics and their public control. *International Economic Review*, 1996.
- [12] P.Y. Geoffard and Tomas Philipson. Disease eradication: private versus public vaccination. *The American Economic Review*, 87(1):222–230, 1997.
- [13] Sanjeev Goyal and Adrien Vigier. Endogenous Interaction and Vaccination. pages 1–34, 2010.
- [14] M. Jackson and D. Lopez-Pintado. Diffusion and Contagion in Networks with Heterogeneous Agents and Homophily. 2011.
- [15] M.O. Jackson and B.W. Rogers. Relating network structure to diffusion properties through stochastic dominance. *The BE Journal of Theoretical Economics*, 7(1):6, 2007.
- [16] M.O. Jackson and Leeat Yariv. Diffusion, strategic interaction, and social structure. *Handbook of Social Economics, Elsevier*, pages 1–50, 2010.
- [17] M. Kremer. Integrating behavioral choice into epidemiological models of AIDS. *The Quarterly Journal of Economics*, 111(2):549, 1996.
- [18] D. López-Pintado. Diffusion in complex social networks. *Games and Economic Behavior*, 62(2):573–590, March 2008.
- [19] P.V. Marsden. Core discussion networks of Americans. *American sociological review*, pages 122–131, 1987.

- [20] P.V. Marsden. Homogeneity in confiding relations. *Social networks*, 10(1):57–76, 1988.
- [21] M. McPherson, L. Smith-Lovin, and J.M. Cook. Birds of a feather: Homophily in social networks. *Annual review of sociology*, pages 415–444, 2001.
- [22] L. Montopoli, S. Bhattacharyya, and C.T. Bauch. The Free Rider Problem In Vaccination Policy And Implications For Global Eradication Of Infectious Diseases: A Two-Country Game Dynamic Model. *Canadian Applied Mathematics Quarterly*, 17(2):317–338, 2009.
- [23] J. Moody. Race, School Integration, and Friendship Segregation in America¹. *American Journal of Sociology*, 107(3):679–716, 2001.
- [24] TC Reluga. An SIS epidemiology game with two subpopulations. *Journal of Biological Dynamics*, 2009.
- [25] R. Rowthorn. The Optimal Treatment of Disease Under a Budget Constraint. In *Explorations in Environmental and Natural Resource Economics: Essays in Honor of Gardner M. Brown, Jr.* Ed. R. Halvorsen and DF Layton. Cheltenham, UK: Edward Elgar Pub, pages 20–35. 2006.
- [26] F Toxvaerd. Infection, Acquired Immunity and Externalities in Treatment. 2010.
- [27] Flavio Toxvaerd. Recurrent Infection and Externalities in Prevention. 2010.
- [28] F Vega-Redondo. *Complex social networks*. Cambridge University Press, 2007.

Appendix A: The Diffusion Model

Proposition 1 The following holds

1. Suppose $\beta < 1/2$. $\pi_A < \pi_B$ iff $\rho_A < \rho_B$ iff $\theta_A < \theta_B$ iff $P_A > P_B$
2. Suppose $\beta > 1/2$. $\pi_A < \pi_B$ iff $\rho_A > \rho_B$ iff $\theta_A > \theta_B$ iff $P_A > P_B$

Proof of proposition 1. We first note that, regardless of β , using the steady state conditions, we have that

$$\rho_A - \rho_B = \frac{\lambda}{(1 + \lambda\theta_A)(1 + \lambda\theta_B)}[\theta_A - \theta_B]$$

and so $\rho_A > \rho_B$ iff $\theta_A > \theta_B$. Next, note that

$$\theta_A - \theta_B = \beta P_A + (1 - \beta)P_B - \beta P_B - (1 - \beta)P_A = (2\beta - 1)(P_A - P_B)$$

so, if $\beta > 1/2$, then $\theta_A > \theta_B$ iff $P_A > P_B$; if $\beta < 1/2$, then $\theta_A < \theta_B$ iff $P_A > P_B$.

We then have that if $\beta > 1/2$, then $\rho_A > \rho_B$ iff $\theta_A > \theta_B$ iff $P_A > P_B$, and if $\beta < 1/2$, then $\rho_A < \rho_B$ iff $\theta_A < \theta_B$ iff $P_A > P_B$.

Consider now the case of $\beta < 1/2$. Suppose that $\rho_A < \rho_B$, then we know that $P_A = (1 - \pi_A)\rho_A > P_B = (1 - \pi_B)\rho_B$, and so it is necessary that $1 - \pi_A > 1 - \pi_B$, or equivalently, $\pi_A < \pi_B$. Suppose now that $\pi_A < \pi_B$ and, for a contradiction, $\rho_A > \rho_B$. Since $\rho_A > \rho_B$ it has to be the case that $P_A = (1 - \pi_A)\rho_A < P_B = (1 - \pi_B)\rho_B$ which requires that $\pi_A > \pi_B$, a contradiction. Hence, if $\beta < 1/2$, then: $\pi_A < \pi_B$ iff $\rho_A < \rho_B$. This concludes the proof of part 1 of the proposition.

We now move to part 2. So, suppose that $\beta > 1/2$. We first show that $\rho_A < \rho_B$ implies that $\pi_B < \pi_A$. Note that

$$\rho_A = \frac{\lambda[\beta(1 - \pi_A)\rho_A + (1 - \beta)(1 - \pi_B)\rho_B]}{1 + \lambda[\beta(1 - \pi_A)\rho_A + (1 - \beta)(1 - \pi_B)\rho_B]} > \frac{\lambda\rho_A[\beta(1 - \pi_A) + (1 - \beta)(1 - \pi_B)]}{1 + \lambda\rho_A[\beta(1 - \pi_A) + (1 - \beta)(1 - \pi_B)]} = \frac{\rho_A\lambda A}{1 + \rho_A\lambda A}$$

where the first inequality follows because we have replaced ρ_B with ρ_A , the expression is increasing in ρ_B and, by assumption $\rho_A < \rho_B$, the second equality follows by simply defining $A = \beta(1 - \pi_A) + (1 - \beta)(1 - \pi_B)$. From the above we infer that

$$\rho_A > \frac{\rho_A \lambda A}{1 + \rho_A \lambda A} \text{ iff } 1 + \lambda \rho_A A > \lambda A \text{ iff } \rho_A > 1 - \frac{1}{\lambda A}$$

Next note that

$$\rho_B = \frac{\lambda[\beta(1 - \pi_B)\rho_B + (1 - \beta)(1 - \pi_A)\rho_A]}{1 + \lambda[\beta(1 - \pi_B)\rho_B + (1 - \beta)(1 - \pi_A)\rho_A]} < \frac{\lambda\rho_B[\beta(1 - \pi_B) + (1 - \beta)(1 - \pi_A)]}{1 + \lambda\rho_B[\beta(1 - \pi_B) + (1 - \beta)(1 - \pi_A)]} = \frac{\rho_B \lambda B}{1 + \rho_B \lambda B}$$

where the first inequality follows because we have replace ρ_A with ρ_B , the expression is increasing in ρ_A and, by assumption $\rho_A < \rho_B$, the second equality follows by simply defining $B = \beta(1 - \pi_B) + (1 - \beta)(1 - \pi_A)$. From the above we infer that

$$\rho_B < \frac{\rho_B \lambda B}{1 + \rho_B \lambda B} \text{ iff } 1 + \lambda \rho_B B < \lambda B \text{ iff } \rho_B < 1 - \frac{1}{\lambda B}.$$

Since, by assumption, $\rho_B > \rho_A$, it is necessary that

$$1 - \frac{1}{\lambda B} > 1 - \frac{1}{\lambda A} \text{ iff } B > A \text{ iff } (2\beta - 1)(\pi_B - \pi_A) < 0 \text{ iff } \pi_B < \pi_A.$$

In a similar way one can prove that $\rho_A > \rho_B$ implies that $\pi_A < \pi_B$ (It is enough to take an upper bound for ρ_A and a lower bound for ρ_B , analogously to the above argument). And so we have that $\rho_A > \rho_B$ iff $\pi_A < \pi_B$. This completes the proof of the proposition. *QED*

Appendix B: The social planner problem

Proof Proposition 2 The proof is divided in three steps.

First step. We start asking what is the minimum mass of immunization needed to eradicate the undesirable state, given an exogenous allocation. Formally, for a total mass of immunizations available to the planner, an allocation is described by a number $\alpha \in \left[\max \left\{ 0, 1 - \frac{1}{\bar{\pi}^*(\alpha)} \right\}, 1/2 \right]$, where $\pi_A = \alpha\pi$ and $\pi_B = (1 - \alpha)\pi$. It is without loss of generality restricting to allocations where $\alpha \leq 1/2$. For a given allocation α , the minimum mass of immunizations needed to eradicate the disease is denoted by $\bar{\pi}^*(\alpha)$ and is the solution to

$$\rho_A(\alpha\bar{\pi}^*(\alpha), (1 - \alpha)\bar{\pi}^*(\alpha)) = \rho_B(\alpha\bar{\pi}^*(\alpha), (1 - \alpha)\bar{\pi}^*(\alpha)) = 0$$

We derive $\bar{\pi}^*(\alpha)$ in the relevant case in which $\bar{\pi}^*(\alpha) > 0$, which is equivalent to require that $\lambda > 1$. We assume this throughout.

For a given π_A and π_B , recall that steady states conditions are

$$\rho_A = \frac{\lambda [\beta(1 - \pi_A)\rho_A + (1 - \beta)(1 - \pi_B)\rho_B]}{1 + \lambda [\beta(1 - \pi_A)\rho_A + (1 - \beta)(1 - \pi_B)\rho_B]}, \quad (4)$$

$$\rho_B = \frac{\lambda [\beta(1 - \pi_B)\rho_B + (1 - \beta)(1 - \pi_A)\rho_A]}{1 + \lambda [\beta(1 - \pi_B)\rho_B + (1 - \beta)(1 - \pi_A)\rho_A]}. \quad (5)$$

Using condition 5, we can express ρ_A as follows

$$\rho_A = \rho_B \left[\frac{1 - \lambda\beta(1 - \pi_B)(1 - \rho_B)}{\lambda(1 - \beta)(1 - \pi_A)(1 - \rho_B)} \right]. \quad (6)$$

Using condition 6 in condition 4 we obtain

$$\rho_A = \frac{\lambda\rho_B \left[\beta \left[\frac{1 - \lambda\beta(1 - \pi_B)(1 - \rho_B)}{\lambda(1 - \beta)(1 - \rho_B)} \right] + (1 - \beta)(1 - \pi_B) \right]}{1 + \lambda [\beta(1 - \pi_A)\rho_A + (1 - \beta)(1 - \pi_B)\rho_B]}. \quad (7)$$

Combining condition 6 with condition 7, we produce

$$\frac{\lambda \left[\beta \left[\frac{1 - \lambda\beta(1 - \pi_B)(1 - \rho_B)}{\lambda(1 - \beta)(1 - \rho_B)} \right] + (1 - \beta)(1 - \pi_B) \right]}{1 + \lambda [\beta(1 - \pi_A)\rho_A + (1 - \beta)(1 - \pi_B)\rho_B]} = \left[\frac{1 - \lambda\beta(1 - \pi_B)(1 - \rho_B)}{\lambda(1 - \beta)(1 - \pi_A)(1 - \rho_B)} \right] \quad (8)$$

Setting $\rho_A = \rho_B = 0$ in 8, we obtain that condition 8 holds if, and only if,

$$1 - \lambda\beta(2 - \bar{\pi}^*(\alpha)) = (1 - \pi_A)(1 - \pi_B)\lambda^2(1 - 2\beta), \quad (9)$$

where $\bar{\pi}^*(\alpha) = \pi_A + \pi_B$; replacing further $\pi_A = \alpha\bar{\pi}^*(\alpha)$ and $\pi_B = \bar{\pi}^*(\alpha) - \pi_A$, we obtain that 9 holds if and only if

$$1 - \lambda\beta(2 - \bar{\pi}^*(\alpha)) = (1 - \alpha\bar{\pi}^*(\alpha))(1 - \bar{\pi}^*(\alpha) + \alpha\bar{\pi}^*(\alpha))\lambda^2(1 - 2\beta)$$

and solving for $\bar{\pi}^*(\alpha)$ we obtain that the minimum mass of immunization needed to eradicate the disease under allocation α is

$$\bar{\pi}^*(\alpha) = \frac{A - \sqrt{A^2 + BC}}{2\lambda(1 - 2\beta)C}, \quad (10)$$

where $A = \beta + \lambda(1 - 2\beta)$, $B = 4(1 - 2\beta)(1 - \lambda\beta - \lambda A)$ and $C = \alpha(1 - \alpha)$. We observe that when $\beta < 1/2$, for $\bar{\pi}^*(\alpha) > 0$ it has to be the case that $A - \sqrt{A^2 + BC} > 0$, whereas when $\beta > 1/2$, for $\bar{\pi}^*(\alpha) > 0$ it has to be the case that $A - \sqrt{A^2 + BC} < 0$.

Second Step. Now that we have derived $\bar{\pi}^*(\alpha)$, we ask which is the allocation that minimizes the the minimum mass of immunization needed to eradicate the disease. Formally, we look for

$$\alpha^* = \arg \min_{\alpha \in [\max\{0, 1 - \frac{1}{\bar{\pi}^*(\alpha)}\}, 1/2]} \bar{\pi}^*(\alpha).$$

Consider the case where $\beta < 1/2$. Note that the sign of the derivative of $\bar{\pi}^*(\alpha)$ with respect to C is the same as the sign of the derivative of $\bar{\pi}^*(\alpha)$ with respect to α (recall that $\alpha \leq 1/2$).

Furthermore,

$$\frac{d\bar{\pi}^*(\alpha)}{dC} = \frac{1}{2\lambda C^2 \sqrt{A^2 + BC}} \frac{1}{1 - 2\beta} \left[BC - 2A\sqrt{A^2 + BC} + 2A^2 \right]$$

Since $1 - 2\beta > 0$, it follows that $\frac{d\bar{\pi}^*(\alpha)}{dC} > 0$ if and only if

$$BC - 2A\sqrt{A^2 + BC} + 2A^2 > 0$$

To see that this is the case note that $BC - 2A\sqrt{A^2 + BC} + 2A^2$ is increasing in C . In fact, simply algebra shows that the derivative of $BC - 2A\sqrt{A^2 + BC} + 2A^2$ with respect to C is positive whenever $B[\sqrt{A^2 + BC} - A] > 0$, which holds because $B < 0$ (as $\lambda > 1$ and $\beta < 1/2$) and $\sqrt{A^2 + BC} - A < 0$ (see observation at the end of step 1). Therefore, $BC - 2A\sqrt{A^2 + BC} + 2A^2 > [BC - 2A\sqrt{A^2 + BC} + 2A^2]_{C=0} = 0$. Hence, if $\beta < 1/2$, the best way to eradicate the disease is to focus first on one group, i.e., $\alpha^* = \max\{0, 1 - \frac{1}{\bar{\pi}^*(\alpha)}\}$.

Consider now the case where $\beta > 1/2$. Recall the expression above for $\frac{d\bar{\pi}^*(\alpha)}{dC}$ and note that, since $1 - 2\beta < 0$, it follows that $\frac{d\bar{\pi}^*(\alpha)}{dC} < 0$ if and only if

$$BC - 2A\sqrt{A^2 + BC} + 2A^2 > 0$$

If B is positive, we can apply the same argument used above to show that indeed $BC - 2A\sqrt{A^2 + BC} + 2A^2 > 0$. Suppose $B < 0$; since $1 - 2\beta < 0$, the fact that $B < 0$ implies that $1 - \lambda\beta - \lambda A > 0$ or, equivalently, $1 - \lambda\beta > \lambda A$. Simple algebra shows that $BC - 2A\sqrt{A^2 + BC} + 2A^2$ is decreasing in A ; so, expression $BC - 2A\sqrt{A^2 + BC} + 2A^2$ is minimised at the highest value that A can take, which is A such that $1 - \lambda\beta = \lambda A$. But at this value $B = 0$ and therefore we have that $BC - 2A\sqrt{A^2 + BC} + 2A^2 > [BC - 2A\sqrt{A^2 + BC} + 2A^2]_{B=0} = 0$. Hence, if $\beta > 1/2$ the best way to eradicate the disease is to split the mass of immunizations across groups, i.e., $\alpha^* = 1/2$.

Third step. Using the expression 10 for $\bar{\pi}^*(\alpha)$ and our conclusion in step 2, we can now

derive the minimum mass of immunization needed to eradicate the disease. In particular, if $\beta > 1/2$, the minimum mass of immunization needed to eradicate the disease is obtained by evaluating $\bar{\pi}^*(\alpha)$ at $\alpha = 1/2$, which gives $\bar{\pi}^* = 2 \left(1 - \frac{1}{\lambda}\right)$. Note that this is independent of β .

Consider the case of $\beta < 1/2$. Then, if the total amount of immunization needed is less than 1, $\bar{\pi}^* < 1$, then, the minimum amount of immunization needed to eradicate the disease is obtain by taking the $\lim_{\alpha \rightarrow 0} \bar{\pi}^*(\alpha)$, which gives us

$$\bar{\pi}^* = 1 - \frac{1}{\lambda} \frac{1 - \lambda\beta}{\lambda(1 - 2\beta) + \beta},$$

which is consistent with our initial hypothesis that $\bar{\pi}^* < 1$ if and only if $\beta < 1/\lambda$. It is easy to verify that $\bar{\pi}^*$ is increasing in β for all $\beta < 1/\lambda$. Finally, suppose that $\bar{\pi}^* > 1$, so that in the optimal assignment $\pi_B = 1$ and $\pi_A = \bar{\pi}^* - 1$. Then, by substituting $\alpha = 1 - \frac{1}{\bar{\pi}^*}$ in expression 10 and then solving it for $\bar{\pi}^*$, we obtain that $\bar{\pi}^* = 2 - \frac{1}{\lambda\beta}$, which is increasing in β . This concludes the proof of the proposition. *QED*

Appendix C: Equilibrium Analysis

Proof of proposition 3 and proposition 4. Proposition 3 and proposition 4 are proved jointly. The proof is divided in two steps. In the first step we characterize all equilibria of our game. The second step selects the stable equilibria.

First step: equilibrium characterization. For $\pi_A = \pi_B = 0$ we have that $\rho_A = \rho_B = \rho^* = 1 - 1/\lambda$. For this to be an equilibrium, it must be that $\rho^* \leq c$, which is equivalent to $\lambda(1 - c) \leq 1$. Note also that when $\lambda(1 - c) < 1$, the only equilibrium is $\pi_A = \pi_B = 0$, since $\pi_g > 0$ implies $\rho_g < 1 - 1/\lambda < c$, contradicting the equilibrium requirement that $\rho_g \geq c$ when $\pi_g > 0$.

We now focus on the case $\lambda(1 - c) > 1$. We start with a characterization of interior equilibria. An interior equilibrium requires that, using (3), $\rho_A = c = \rho_B$, which implies by (2) that $\theta_A = \theta_B$, which, using (1) and provided $\beta \neq 1/2$, implies that $\pi_A = \pi_B$. Setting $\pi_A = \pi_B = \pi^*$ and solving $\rho_A = c$ produces

$$\pi^* = 1 - \frac{1}{\lambda(1 - c)}.$$

Thus provided $\beta \neq 1/2$, for $\lambda(1 - c) > 1$ there exists a unique interior equilibrium, in which case it is symmetric. Next, it is never an equilibrium for $\pi_A = \pi_B = 1$, since any player could profitably deviate by not immunizing, given that all other players are immunized.

The only remaining possibility for equilibria are therefore asymmetric. Without loss of generality, we focus on the case $\pi_A < \pi_B$. By the above, any additional equilibrium must be such that either $\pi_A = 0$ or $\pi_B = 1$, as otherwise it would be interior and therefore not asymmetric. There are therefore three possibilities: (1) $\pi_A = 0$ and $\pi_B \in (0, 1)$, (2) $\pi_A = 0$ and $\pi_B = 1$, and (3) $\pi_A \in (0, 1)$ and $\pi_B = 1$. We consider each of these possibilities in turn.

Case 1. Suppose $\pi_A = 0$ and $\pi_B \in (0, 1)$. In equilibrium $\rho_B = c$. Using this and the

steady-state conditions (2) we obtain that the following two conditions must hold

$$\rho_A = \frac{\lambda[\beta\rho_A + (1 - \beta)(1 - \pi_B)c]}{1 + \lambda[\beta\rho_A + (1 - \beta)(1 - \pi_B)c]}, \quad (11)$$

$$c = \frac{\lambda[\beta(1 - \pi_B)c + (1 - \beta)\rho_A]}{1 + \lambda[\beta(1 - \pi_B)c + (1 - \beta)\rho_A]}. \quad (12)$$

Solving condition (11) for π_B we obtain

$$\hat{\pi}_B(\rho_A) = \frac{\lambda c(1 - \beta) - \lambda\beta\rho_A^2 + \rho_A(\lambda\beta(1 + c) - 1 - \lambda c)}{\lambda c(1 - \beta)(1 - \rho_A)},$$

and, similarly, solving condition (12) for π_B we obtain

$$\tilde{\pi}_B(\rho_A) = 1 - \frac{1}{\lambda\beta(1 - c)} + \frac{1 - \beta}{\beta c}\rho_A.$$

Note that an equilibrium is defined by $\pi_B = \pi^*$ and $\rho_A = \rho^*$ such that $\hat{\pi}_B(\rho^*) = \tilde{\pi}_B(\rho^*) = \pi^* \in (0, 1)$ and $\rho^* \in (0, c]$, where $\rho^* \leq c$ is required for $\pi_A = 0$ to be consistent with equilibrium.

Note that $\hat{\pi}_B(0) = 1$, $\hat{\pi}_B(c) = \frac{\lambda(1-c)-1}{\lambda(1-c)(1-\beta)} > 0$ and $\hat{\pi}_B(\rho)$ is strictly concave in $\rho \in [0, c]$. Thus $\hat{\pi}_B(\rho) > 0$ for all $\rho \in [0, c]$. Also note that $\tilde{\pi}_B(0) = 1 - \frac{1}{\lambda\beta(1-c)} < \hat{\pi}_B(0)$, $\tilde{\pi}_B(c) = \frac{\lambda(1-c)-1}{\lambda(1-c)\beta}$ and $\tilde{\pi}_B(\rho)$ is linear and strictly increasing in $\rho \in [0, c]$. Thus there is at most one such equilibrium (π^*, ρ^*) .

A necessary condition for equilibrium is that $\hat{\pi}_B(c) \leq \tilde{\pi}_B(c)$ which is equivalent to $\beta \leq 1/2$. So suppose $\beta \leq 1/2$. Recall that ρ^* solves $\hat{\pi}_B(\rho^*) = \tilde{\pi}_B(\rho^*)$, which is well-defined and in $(0, c]$. Define $\tilde{\rho}$ such that $\tilde{\pi}_B(\tilde{\rho}) = 1$, which gives

$$\tilde{\rho} = \frac{c}{\lambda(1 - c)(1 - \beta)}.$$

Define

$$\Psi(\beta, c, \lambda) = (1 - \beta)(1 - c)[\beta\lambda - 1] - \beta c,$$

and notice that $\hat{\pi}_B(\tilde{\rho}) < 1$ if and only if $\Psi(\beta, c, \lambda) < 0$.

The equilibrium exists if and only if $\tilde{\pi}_B(\rho^*) < 1$, i.e., $\tilde{\pi}_B(\rho^*) < \tilde{\pi}_B(\tilde{\rho})$. Since $\tilde{\pi}_B$ is strictly increasing, this is equivalent to $\rho^* < \tilde{\rho}$. This is equivalent to $\hat{\pi}_B(\tilde{\rho}) < \tilde{\pi}_B(\tilde{\rho}) = 1$. Finally, by the definition of Ψ , this is equivalent to $\Psi(\beta, c, \lambda) < 0$.

The following lemma provides the region of parameters in which this condition is satisfied.

Lemma 1 *Suppose $\beta \in [0, 1/2)$ and $\lambda(1 - c) > 1$; let $\Psi(\beta, c, \lambda) = (1 - \beta)(1 - c)[\beta\lambda - 1] - \beta c$.*

1. *Suppose $c < 1/2$.*

1.1 *If $\lambda(1 - c) < 2$ then $\Psi(\beta, c, \lambda) < 0$.*

1.2 *If $\lambda(1 - c) > 2$ then there exists $\underline{\beta} \in (0, 1/2)$ such that $\Psi(\underline{\beta}, c, \lambda) = 0$, and $\Psi(\beta, c, \lambda) < 0$ if and only if $\beta \in [0, \underline{\beta})$.*

2. *Suppose $c > 1/2$.*

2.1 *If $\lambda(1 - c) < [1 + 2(c(1 - c))^{1/2}]$ then $\Psi(\beta, c, \lambda) < 0$.*

2.2 *If $\lambda(1 - c) \in [[1 + 2(c(1 - c))^{1/2}], 2]$ then there exists $0 < \underline{\beta} < \bar{\beta} < 1/2$ such that $\Psi(\underline{\beta}, c, \lambda) = \Psi(\bar{\beta}, c, \lambda) = 0$, and $\Psi(\beta, c, \lambda) \leq 0$ if and only if $\beta < \underline{\beta}$ or $\beta > \bar{\beta}$.*

2.3 *If $\lambda(1 - c) > 2$ then there exists $\underline{\beta} \in (0, 1/2)$ such that $\Psi(\underline{\beta}, c, \lambda) = 0$, and $\Psi(\beta, c, \lambda) \leq 0$ if and only if $\beta < \underline{\beta}$.*

Proof of Lemma 1. The following two observations are used in the proof.

Observation 1. $\Psi(0, c, \lambda) = -(1 - c) < 0$, $\Psi(1/2, c, \lambda) = \frac{1-c}{2} \left[\frac{\lambda}{2} - 1 \right] - \frac{c}{2}$, which is negative iff $\lambda(1 - c) \leq 2$.

Observation 2.

$$\frac{\partial \Psi(\beta, c, \lambda)}{\partial \beta} = (1 - c)[1 + \lambda(1 - 2\beta)] - c,$$

which is positive if $c \leq 1/2$, whereas if $c > 1/2$ it is positive for low β and negative for high β (still below $1/2$).

First suppose that $\lambda(1 - c) > 2$; observations 1-2 imply that there exists a $\underline{\beta} < 1/2$ such that $\Psi(\underline{\beta}, c, \lambda) = 0$ and that $\Psi(\beta, c, \lambda) < 0$ if and only if $\beta < \underline{\beta}$; this proves part 1.2. and part 2.3. Second suppose that $c < 1/2$ and $\lambda(1 - c) < 2$; observations 1-2 imply that $\Psi(\beta, c, \lambda) < 0$ for all $\beta < 1/2$, which proves part 1.1.

Third, suppose that $c > 1/2$ and $\lambda(1 - c) < 2$. Recall that observation 1 and observation 2 tell us that $\Psi(0, c, \lambda) < 0$, $\Psi(1/2, c, \lambda) < 0$, and $\Psi(\beta, c, \lambda)$ is first increasing and then decreasing in β . So, there are two possibilities. One possibility is that the maximum value of $\Psi(\beta, c, \lambda)$ is negative, in which case $\Psi(\beta, c, \lambda) < 0$. The other possibility is that the maximum value of $\Psi(\beta, c, \lambda)$ is positive, in which case there exist $\underline{\beta} < \bar{\beta} < 1/2$ such that $\Psi(\underline{\beta}, c, \lambda) = \Psi(\bar{\beta}, c, \lambda) = 0$ and, $\Psi(\beta, c, \lambda) < 0$ for all $\beta < \underline{\beta}$ and for all $\beta > \bar{\beta}$. To distinguish between these two cases, define $\beta^* = \arg \max_{\beta \in [0, 1/2]} \Psi(\beta, c, \lambda)$. This is given by

$$\beta^* = \frac{1}{2} - \frac{2c - 1}{2\lambda(1 - c)},$$

and note that

$$\Psi(\beta^*, c, \lambda) = \frac{1}{2\lambda(1 - c)} \left[\frac{1 - c}{2} (\lambda(1 - c) + 2c - 1) \left(\lambda - \frac{1}{1 - c} \right) - c(\lambda(1 - c) - 2c + 1) \right].$$

It is now easy to verify that $\Psi(\beta^*, c, \lambda) \leq 0$ iff $\lambda(1 - c) < 1 + 2(c(1 - c))^{1/2}$. This concludes part 2.1 and 2.2. The proof of lemma 1 is now completed. *QED*

Case 2. Suppose $\pi_A = 0$ and $\pi_B = 1$. For equilibrium $\rho_A \leq c \leq \rho_B$; if $\beta > 1/2$ then $\theta_B < \theta_A$ which implies that $\rho_B < \rho_A$, a contradiction. Hence, $\beta \leq 1/2$; using the steady state condition 2 we obtain

$$\rho_A = \frac{\lambda\beta - 1}{\lambda\beta},$$

and we can then derive ρ_B as

$$\rho_B = \frac{(1 - \beta)(\lambda\beta - 1)}{\beta + (1 - \beta)(\lambda\beta - 1)}.$$

Since $\rho_A \in (0, c]$, then $\beta > \frac{1}{\lambda}$ and $\beta \leq \hat{\beta} = \frac{1}{\lambda(1-c)}$. Since $\rho_B \geq c$ then $\Psi(\beta, c, \lambda) \geq 0$. Using Lemma 1, we conclude that $\beta > \frac{1}{\lambda}$, $\beta \leq \hat{\beta} = \frac{1}{\lambda(1-c)}$ and $\Psi(\beta, c, \lambda) \geq 0$ if and only if $\lambda(1-c) > 2$ and $\beta \in [\underline{\beta}, \hat{\beta}]$, where we recall that $\Psi(\underline{\beta}, c, \lambda) = 0$.

Case 3. Suppose $\pi_A \in (0, 1)$ and $\pi_B = 1$. In equilibrium $\rho_A = c \leq \rho_B$ and a necessary condition for $\rho_A \leq \rho_B$ is that $\beta \leq 1/2$. So, let $\beta \leq 1/2$. Solving for $\rho_A = c$ we obtain

$$\pi_A = 1 - \frac{1}{\lambda\beta(1-c)},$$

and $\pi_A \in (0, 1)$ if and only if $\beta > \hat{\beta} = \frac{1}{\lambda(1-c)}$. It is easy to check that $\rho_B \geq c$ for all $\beta \leq 1/2$. Note that $\hat{\beta} \leq 1/2$ if and only if $\lambda(1-c) > 2$. So, this equilibrium exists whenever $\lambda(1-c) > 2$ and $\beta \in (\hat{\beta}, 1/2]$.

This concludes the characterization of equilibria.

Second step: stability. The equilibrium characterisation shows that: 1. there is only one interior equilibrium and the interior equilibrium exists for all β , 2. for $\beta > 1/2$ the equilibrium is unique, 3. for $\beta < 1/2$ there is only one (upon relabelling) asymmetric equilibrium. Hence, to prove the result on global stability, it is sufficient to show that the derivative of the best response of group B with respect to group A 's immunization rate, evaluated at the interior equilibrium, is larger than -1 iff $\beta > 1/2$. Formally,

$$\left. \frac{d\pi_B^*(\pi_A)}{d\pi_A} \right|_{\pi_A=\pi_B=\pi^*} > -1 \text{ if, and only if, } \beta > 1/2.$$

What follows show that this relation holds. We first observe that for every $(\pi_B^*(\pi_A), \pi_A)$ with π_A sufficiently close to the interior equilibrium value π^* , we have that $\rho_B(\pi_B^*(\pi_A), \pi_A) = c$, i.e., the proportion of infected agents of group B who are not immunized does not change with π_A , taking into account that immunization in B is optimal given π_A . This directly implies

that $\theta_B(\pi_B^*(\pi_A), \pi_A)$ is also constant when π_A is sufficiently close to π^* , i.e.,

$$\frac{d\theta_B(\pi_B^*(\pi_A), \pi_A)}{d\pi_A}\Big|_{\pi^*} = 0.$$

Note that

$$\begin{aligned} \frac{d\theta_B(\pi_B^*(\pi_A), \pi_A)}{d\pi_A} &= -\beta c \frac{d\pi_B^*(\pi_A)}{d\pi_A} + (1 - \beta) \left[(1 - \pi_A) \frac{d\rho_A(\pi_A, \pi_B^*(\pi_A))}{d\pi_A} - \rho_A \right], \\ \frac{d\rho_A(\pi_A, \pi_B^*(\pi_A))}{d\pi_A} &= \frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_A} + \frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_B} \frac{d\pi_B^*}{d\pi_A}, \end{aligned}$$

and that at π^* we have that $\rho_A = c$. Hence, $\frac{d\theta_B(\pi_B^*(\pi_A), \pi_A)}{d\pi_A}\Big|_{\pi^*} = 0$ if, and only if,

$$\frac{d\pi_B^*(\pi_A)}{d\pi_A}\Big|_{\pi^*} = \frac{(1 - \beta) \left[(1 - \pi^*) \frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_A}\Big|_{\pi^*} - c \right]}{\beta c - (1 - \beta)(1 - \pi^*) \frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_B}\Big|_{\pi^*}}.$$

Next, $\frac{d\pi_B^*(\pi_A)}{d\pi_A}\Big|_{\pi^*} > -1$ if, and only if,

$$(1 - \beta) \left[(1 - \pi^*) \frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_A}\Big|_{\pi^*} - c \right] > (1 - \beta)(1 - \pi^*) \frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_B}\Big|_{\pi^*} - \beta c$$

or equivalently,

$$(1 - \beta)(1 - \pi^*) \left[\frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_A}\Big|_{\pi^*} - \frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_B}\Big|_{\pi^*} \right] > c(1 - 2\beta).$$

Using the fact that $\rho_A = \lambda\theta_A/[\lambda\theta_A + 1]$ and that $\theta_A = \beta(1 - \pi_A)\rho_A + (1 - \beta)(1 - \pi_B)\rho_B$, we obtain

$$\frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_A}\Big|_{\pi^*} - \frac{\partial \rho_A(\pi_A, \pi_B^*(\pi_A))}{\partial \pi_B}\Big|_{\pi^*} = \frac{c(1 - 2\beta)}{(1 + \lambda\theta_A(\pi^*))^2}$$

and so, we can rewrite the condition above as

$$(1 - \beta)(1 - \pi^*) \frac{c(1 - 2\beta)}{(1 + \lambda\theta_A(\pi^*))^2} > c(1 - 2\beta).$$

which holds if and only if $\beta > 1/2$. This completes the proof for stability. *QED.*

Proof of proposition 5. In view of proposition 4 we consider two cases. The first case is when in equilibrium $\pi_B = 1$. Since $\pi_B = 1$, then $P_B = 0$ and $W_B = 1 - c$. Prevalence in group A must be positive, for otherwise $\rho_B = 0 < c$, which contradicts equilibrium. So group A 's prevalence is higher than group B 's prevalence. Furthermore, if $\pi_A > 0$, then $\rho_A = c$ and so $W_A = W_B$. If $\pi_A = 0$, then equilibrium implies that $\rho_A < c$, and so $W_A > W_B$. The second case is when in equilibrium $\pi_B \in (0, 1)$. Since $\pi_B \in (0, 1)$, equilibrium implies that $\rho_B = c$ and therefore $P_B = (1 - \pi_B)c$ and $W_B = 1 - c$. Furthermore, if $\pi_B \in (0, 1)$ then $\pi_A = 0$ and so $\rho_A < c$. Hence, $W_A = 1 - \rho_A > 1 - c = W_B$. Finally, since $\rho_A < c = \rho_B$ it follows that $\theta_B > \theta_A$. Given that $\beta < 1/2$ and that $\theta_B - \theta_A = (P_B - P_A)(2\beta - 1)$, we have that $\theta_B > \theta_A$ if and only if $P_A > P_B$. This completes the proof of proposition 5. *QED.*

Proof of proposition 6. In view of proposition 4 we observe that since $\pi_B > 0$, $W_B = 1 - c$. We now consider three cases. The first case is when $\pi_A = 0$ and $\pi_B = 1$; in this case $P_A = \rho_A = 1 - \frac{1}{\lambda\beta}$ proving that P_A increases in β and welfare $W_A = 1 - P_A$ is decreasing. The second case is when $\pi_B = 1$ and $\pi_A \in (0, 1)$. The welfare is $W_A = 1 - c$; the prevalence is $P_A = (1 - \pi_A)\rho_A = (1 - \pi_A)c$. Since $\pi_A = 1 - \frac{1}{\lambda\beta(1-c)}$, an increase in β , increases π_A , and so it decreases P_A . The last case is when $\pi_A = 0$ and $\pi_B \in (0, 1)$. The welfare is $W_A = 1 - \rho_A$ and $P_A = \rho_A$. Solving equilibrium conditions 11 and 12 we obtain an explicit solution for ρ_A . Taking the derivative with respect to β , one can show that the sign of $\frac{d\rho_A}{d\beta}$ is the opposite of the sign of

$$F(\beta) = c + \gamma(1 - 2c) + \beta(1 - 2\gamma)(1 - 2c) - \sqrt{-4\gamma c(1 - \beta)(1 - 2\beta) + [\beta + (1 - 2\beta)(c + \gamma)]^2},$$

where $\gamma = \lambda(1 - c)$. By inspection $F(\beta) < 0$ for all $\beta < 1/2$, which shows that ρ_A is increasing in β .

To conclude the proof we note that if $\lambda(1 - c) < 2$, the equilibrium characterisation implies that in equilibrium $\pi_A = 0$, and so the proof follows. If $\lambda(1 - c) > 2$ in equilibrium $\pi_A = 0$ if

and only if $\beta < 1/\lambda(1 - c)$. This concludes the proof of proposition 6. *QED*

Proof of Proposition 7. Solving the equilibrium conditions of an interior equilibrium together with the steady state conditions we obtain:

$$\pi_A = 1 - \frac{c_A(1 - c_B)\beta - (1 - \beta)c_B(1 - c_A)}{k\lambda(2\beta - 1)c_A(1 - c_A)(1 - c_B)} \quad (13)$$

$$\pi_B = 1 - \frac{c_B(1 - c_A)\beta - (1 - \beta)c_A(1 - c_B)}{k\lambda(2\beta - 1)c_B(1 - c_A)(1 - c_B)} \quad (14)$$

By investigation of these two expressions it is easy to check that for all $\beta \in (1/2, 1]$ the following holds: (1.) $\pi_B > \pi_A$, (2.) π_B is decreasing in β , while π_A is increasing in β . Next, define $\bar{\beta}$ be such that $\pi_B(\bar{\beta}) = 1$. Solving we obtain that

$$\bar{\beta} = \frac{c_A(1 - c_B)}{c_A(1 - c_B) + c_B(1 - c_A)} > 1/2,$$

and that $\pi_A(\bar{\beta}) > 0$. These considerations imply that for all $\beta \in [\bar{\beta}, 1]$ there exists an interior equilibrium, π_A and π_B are defined by expression 13 and 14, and $\pi_B > \pi_A$. We now show that for all $\beta \in [1/2, \bar{\beta}]$ there exists an equilibrium where $\pi_B = 1$ and $\pi_A \in (0, 1)$. Suppose $\pi_B = 1$ and $\pi_A \in (0, 1)$. For equilibrium, $\rho_A = c_A$; solving the equilibrium condition for π_A we obtain that

$$\pi_A = 1 - \frac{1}{\lambda k \beta (1 - c_A)}, \quad (15)$$

and this implies that

$$\rho_B = \frac{(1 - \beta)c_A}{\beta(1 - c_A) + (1 - \beta)c_A} \geq c_B$$

if and only if $\beta < \bar{\beta}$. Again, note that at $\beta = 1/2$, π_A is still positive. It is easy to establish that for $\beta > 1/2$ there is only one equilibrium. This concludes the proof of the proposition 7. *QED*.

Proof of Corollary 1. Using proposition 7 and taking the difference between the equilibrium

immunization rate of group B and group A is easy to verify that this equals $\Delta_\pi \Phi_\pi(\beta, c_A, c_B)$, where

$$\Phi_\pi(\beta, c_A, c_B) = \begin{cases} \frac{1-c_B}{\beta(c_A-c_B)}, & \text{if } \beta \in (1/2, \bar{\beta}) \\ \frac{c_A c_B (2\beta-1) + (1-\beta)(c_B+c_A)}{c_A c_B (2\beta-1)}, & \text{if } \beta > \bar{\beta} \end{cases}$$

and that $\Phi_\pi(\beta, c_A, c_B) > 1$ and it is decreasing and convex in β . Similarly, taking the difference between the equilibrium prevalence of group A and group B it is easy to verify that it equals the product of Δ_P and a social multiplier $\Phi_P(\beta, c_A, c_B)$, where

$$\Phi_P(\beta, c_A, c_B) = \begin{cases} \frac{c_A(1-c_B)}{\beta(c_A-c_B)}, & \text{if } \beta \in (1/2, \bar{\beta}) \text{ is even} \\ \frac{1}{2\beta-1}, & \text{if } \beta > \bar{\beta} \end{cases}$$

and that $\Phi_P(\beta, c_A, c_B) > 1$ and it is decreasing and convex in β . Finally, direct computation shows that the difference between the equilibrium welfare of group A and of group B equals $c_A - c_B$ and therefore it is constant in β . *QED*.